NVP-BEZ235 (PI3K/mTOR inhibitor) treatment demonstrated a significant decrease in the growth of GSCs derived from patient samples in xenograft models.134 Importantly, the Yamanaka stem cell factors were used to generate CSCs for understanding the molecular basis of CSCs in human breast cancer cells. Here, MTOR is linked to breast carcinoma.